ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
ProQR Therapeutics N.V. (Nasdaq:PRQR) will present a virtual paper on April 10, 2021, at the AAPOS annual meeting. The presentation focuses on the innovative genetic therapy using antisense oligonucleotide treatment for Leber Congenital Amaurosis 10 (LCA10), specifically targeting the prevalent p.Cys998X mutation in the CEP290 gene. This condition leads to significant vision loss in children, and there are currently no approved treatments. ProQR's investigational RNA therapy, Sepofarsen, aims to address this gap and has received multiple designations from regulatory authorities.
- Presentation on transformative genetic therapy for LCA10 could enhance visibility among investors and the medical community.
- Sepofarsen is in pivotal Phase 2/3 Illuminate trial, indicating advancement in clinical development.
- Regulatory designations (orphan drug, fast-track, rare pediatric disease) for Sepofarsen may speed up approval process.
- Currently, there are no approved treatments for LCA10, indicating a competitive risk as the first entrant.
- The success of Sepofarsen is contingent on the clinical trial outcomes, which carry inherent uncertainties.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021.
ProQR’s presentation
Presentation title: A different type of genetic therapy: correcting a defective gene using antisense oligonucleotide treatment in CEP290 p.Cys998X LCA
Presenter: Arlene V. Drack, MD, Ronald Keech Professor of Pediatric Genetic Eye Disease Department of Ophthalmology and Visual Sciences, University of Iowa
Presentation type: Oral paper presentation
Date: April 10, 2021 at 1:23pm EDT. The presentation will be available for viewing until July 15, 2021.
About Leber Congenital Amaurosis 10 (LCA10)
Leber congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children. It consists of a group of diseases of which LCA10 is the most frequent and one of the most severe forms. LCA10 is caused by mutations in the CEP290 gene, of which the p.Cys998X mutation has the highest prevalence. LCA10 leads to early loss of vision causing most people to lose their sight in the first few years of life. To date, there are no treatments approved that treat the underlying cause of the disease. Approximately 2,000 people in the Western world have LCA10 because of this mutation.
About Sepofarsen
Sepofarsen (QR-110) is being evaluated in the pivotal Phase 2/3 Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. The p.Cys998X mutation leads to aberrant splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting in restoration of normal (wild type) CEP290 mRNA and subsequent production of functional CEP290 protein. Sepofarsen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include those relating to our presentation at AAPOS. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com
Media Contact:
Cherilyn Cecchini, MD
LifeSci Communications
T: +1 646 876 5196
ccecchini@lifescicomms.com
FAQ
What is the date of ProQR's presentation at AAPOS 2021?
What is the focus of ProQR's presentation at the AAPOS meeting?
What company is conducting the Illuminate trial for Sepofarsen?
What is Sepofarsen designed to treat?
What regulatory designations has Sepofarsen received?
